376 related articles for article (PubMed ID: 27956089)
21. Long-term follow-up and role of FDG PET in advanced pancreatic neuroendocrine patients treated with
Sansovini M; Severi S; Ianniello A; Nicolini S; Fantini L; Mezzenga E; Ferroni F; Scarpi E; Monti M; Bongiovanni A; Cingarlini S; Grana CM; Bodei L; Paganelli G
Eur J Nucl Med Mol Imaging; 2017 Mar; 44(3):490-499. PubMed ID: 27704193
[TBL] [Abstract][Full Text] [Related]
22. Carcinoid of the pancreas.
Migliori M; Tomassetti P; Lalli S; Casadei R; Santini D; Corinaldesi R; Gullo L
Pancreatology; 2002; 2(2):163-6. PubMed ID: 12123097
[TBL] [Abstract][Full Text] [Related]
23. [Pulmonary carcinoid tumors].
Prosch H
Radiologe; 2017 May; 57(5):397-406. PubMed ID: 28405692
[TBL] [Abstract][Full Text] [Related]
24. Current diagnosis and treatment of gastrointestinal carcinoids in a series of 101 patients: the significance of serum chromogranin-A, somatostatin receptor scintigraphy and somatostatin analogues.
Nikou GC; Lygidakis NJ; Toubanakis C; Pavlatos S; Tseleni-Balafouta S; Giannatou E; Mallas E; Safioleas M
Hepatogastroenterology; 2005; 52(63):731-41. PubMed ID: 15966194
[TBL] [Abstract][Full Text] [Related]
25. Induction of apoptosis in neuroendocrine tumors of the digestive system during treatment with somatostatin analogs.
Imam H; Eriksson B; Lukinius A; Janson ET; Lindgren PG; Wilander E; Oberg K
Acta Oncol; 1997; 36(6):607-14. PubMed ID: 9408151
[TBL] [Abstract][Full Text] [Related]
26. Octreotide and Lanreotide in Gastroenteropancreatic Neuroendocrine Tumors.
Pokuri VK; Fong MK; Iyer R
Curr Oncol Rep; 2016 Jan; 18(1):7. PubMed ID: 26743514
[TBL] [Abstract][Full Text] [Related]
27. Somatostatin-receptor-based imaging and therapy of gastroenteropancreatic neuroendocrine tumors.
Kwekkeboom DJ; Kam BL; van Essen M; Teunissen JJ; van Eijck CH; Valkema R; de Jong M; de Herder WW; Krenning EP
Endocr Relat Cancer; 2010 Mar; 17(1):R53-73. PubMed ID: 19995807
[TBL] [Abstract][Full Text] [Related]
28. Different response to the long-acting somatostatin analogues lanreotide and octreotide in a patient with a malignant carcinoid.
Raderer M; Kurtaran A; Scheithauer W; Fiebiger W; Weinlaender G; Oberhuber G
Oncology; 2001; 60(2):141-5. PubMed ID: 11244329
[TBL] [Abstract][Full Text] [Related]
29. Response and relapse rates after treatment with long-acting somatostatin analogs in multifocal or recurrent type-1 gastric carcinoids: A systematic review and meta-analysis.
Rossi RE; Invernizzi P; Mazzaferro V; Massironi S
United European Gastroenterol J; 2020 Mar; 8(2):140-147. PubMed ID: 32213066
[TBL] [Abstract][Full Text] [Related]
30. Correlation of somatostatin receptor PET/CT imaging features and immunohistochemistry in neuroendocrine tumors of the lung: a retrospective observational study.
Rufini V; Lorusso M; Inzani F; Pasciuto T; Triumbari EKA; Grillo LR; Locco F; Margaritora S; Pescarmona E; Rindi G
Eur J Nucl Med Mol Imaging; 2022 Oct; 49(12):4182-4193. PubMed ID: 35674739
[TBL] [Abstract][Full Text] [Related]
31. The expanding role of somatostatin analogs in gastroenteropancreatic and lung neuroendocrine tumors.
Cives M; Strosberg J
Drugs; 2015 May; 75(8):847-58. PubMed ID: 25911185
[TBL] [Abstract][Full Text] [Related]
32. Somatostatin receptor scintigraphy with 111In-octreotide in pulmonary carcinoid tumours correlated with pathological and 18FDG PET/CT findings.
Kuyumcu S; Adalet I; Sanli Y; Turkmen C; Ozkan ZG; Yilmazbayhan D
Ann Nucl Med; 2012 Nov; 26(9):689-97. PubMed ID: 22802007
[TBL] [Abstract][Full Text] [Related]
33. Somatostatin Analogues in the Treatment of Neuroendocrine Tumors: Past, Present and Future.
Stueven AK; Kayser A; Wetz C; Amthauer H; Wree A; Tacke F; Wiedenmann B; Roderburg C; Jann H
Int J Mol Sci; 2019 Jun; 20(12):. PubMed ID: 31234481
[TBL] [Abstract][Full Text] [Related]
34. Comparison of survival with somatostatin analog and chemotherapy and prognostic factors for treatment in 165 advanced neuroendocrine tumor patients with Ki-67 20% or less.
Özaslan E; Karaca H; Koca S; Sevinç A; Hacioğlu B; Özkan M; Özçelik M; Duran AO; Hacibekiroğlu İ; Yildiz Y; Tanriverdi Ö; Menekşe S; Aksoy A; Bozkurt O; Urvay S; Uysal M; Demir H; Çiltaş A; Dane F
Anticancer Drugs; 2017 Feb; 28(2):222-229. PubMed ID: 27768606
[TBL] [Abstract][Full Text] [Related]
35. Long-acting somatostatin analogues in the treatment of unresectable/metastatic neuroendocrine tumors.
Enzler T; Fojo T
Semin Oncol; 2017 Apr; 44(2):141-156. PubMed ID: 28923213
[TBL] [Abstract][Full Text] [Related]
36. Changes in biodistribution on
Cherk MH; Kong G; Hicks RJ; Hofman MS
Cancer Imaging; 2018 Jan; 18(1):3. PubMed ID: 29361984
[TBL] [Abstract][Full Text] [Related]
37. EVALUATION OF LANREOTIDE DEPOT/AUTOGEL EFFICACY AND SAFETY AS A CARCINOID SYNDROME TREATMENT (ELECT): A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL.
Vinik AI; Wolin EM; Liyanage N; Gomez-Panzani E; Fisher GA;
Endocr Pract; 2016 Sep; 22(9):1068-80. PubMed ID: 27214300
[TBL] [Abstract][Full Text] [Related]
38. Predictive value of 18F-FDG PET and somatostatin receptor scintigraphy in patients with metastatic endocrine tumors.
Garin E; Le Jeune F; Devillers A; Cuggia M; de Lajarte-Thirouard AS; Bouriel C; Boucher E; Raoul JL
J Nucl Med; 2009 Jun; 50(6):858-64. PubMed ID: 19443590
[TBL] [Abstract][Full Text] [Related]
39. Chemotherapy and biotherapy in the treatment of neuroendocrine tumours.
Oberg K
Ann Oncol; 2001; 12 Suppl 2():S111-4. PubMed ID: 11762335
[TBL] [Abstract][Full Text] [Related]
40. Metastatic Medullary Thyroid Cancer: The Role of 68Gallium-DOTA-Somatostatin Analogue PET/CT and Peptide Receptor Radionuclide Therapy.
Hayes AR; Crawford A; Al Riyami K; Tang C; Bomanji J; Baldeweg SE; Wild D; Morganstein D; Harry A; Grozinsky-Glasberg S; Oleinikov K; Khoo B; Caplin ME; Nicolas GP; Grossman AB
J Clin Endocrinol Metab; 2021 Nov; 106(12):e4903-e4916. PubMed ID: 34379772
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]